127 related articles for article (PubMed ID: 27940401)
1. DNA damage induced by NADPH cytochrome P450 reductase-activated idarubicin in sensitive and multidrug resistant MCF7 breast cancer cells.
Żwierełło W; Maruszewska A; Nowak R; Kostrzewa-Nowak D; Tarasiuk J
Pharmacol Rep; 2017 Feb; 69(1):185-195. PubMed ID: 27940401
[TBL] [Abstract][Full Text] [Related]
2. The role of bioreductive activation of antitumour anthracycline drugs in cytotoxic activity against sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Bieg B; Paine MJ; Wolf CR; Tarasiuk J
Eur J Pharmacol; 2012 Jan; 674(2-3):112-25. PubMed ID: 22115891
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the protective effects of quercetin, rutin, naringenin, resveratrol and trolox against idarubicin-induced DNA damage.
Celik H; Arinç E
J Pharm Pharm Sci; 2010; 13(2):231-41. PubMed ID: 20816008
[TBL] [Abstract][Full Text] [Related]
4. Bioreduction of idarubicin and formation of ROS responsible for DNA cleavage by NADPH-cytochrome P450 reductase and its potential role in the antitumor effect.
Celik H; Arinç E
J Pharm Pharm Sci; 2008; 11(4):68-82. PubMed ID: 19183515
[TBL] [Abstract][Full Text] [Related]
5. Bioreductive activation of mitoxantrone by NADPH cytochrome P450 reductase does not change its apoptotic stimuli properties in regard to sensitive and multidrug resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Tarasiuk J
Eur J Pharmacol; 2013 Dec; 721(1-3):141-50. PubMed ID: 24076328
[TBL] [Abstract][Full Text] [Related]
6. Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.
Lacayo NJ; Duran GE; Sikic BI
J Exp Ther Oncol; 2003; 3(3):127-35. PubMed ID: 14641819
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance.
Ross DD; Doyle LA; Yang W; Tong Y; Cornblatt B
Biochem Pharmacol; 1995 Nov; 50(10):1673-83. PubMed ID: 7503771
[TBL] [Abstract][Full Text] [Related]
8. Bioreductive Activation of Antitumour Drugs, Doxorubicin and Pirarubicin, Does Not Affect Their Ability to Induce Apoptosis of Sensitive and Multidrug Resistant Leukaemia HL60 Cells.
Kostrzewa-Nowak D; Tarasiuk J
Anticancer Res; 2021 Mar; 41(3):1429-1438. PubMed ID: 33788734
[TBL] [Abstract][Full Text] [Related]
9. Role of structural factors of antitumour anthraquinone derivatives and analogues in the ability to undergo bioreductive activation by NADPH cytochrome P450 reductase: implications for increasing the activity against sensitive and multidrug-resistant leukaemia HL60 cells.
Kostrzewa-Nowak D; Bieg B; Paine MJ; Wolf CR; Tarasiuk J
Anticancer Drugs; 2012 Apr; 23(4):393-405. PubMed ID: 22205152
[TBL] [Abstract][Full Text] [Related]
10. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line.
Gewirtz DA; Randolph JK; Chawla J; Orr MS; Fornari FA
Cancer Chemother Pharmacol; 1998; 41(5):361-9. PubMed ID: 9523731
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of selected plant polyphenols, gallic acid and epigallocatechin gallate, on matrix metalloproteinases activity in multidrug resistant MCF7/DOX breast cancer cells.
Nowakowska A; Tarasiuk J
Acta Biochim Pol; 2016; 63(3):571-5. PubMed ID: 27231728
[TBL] [Abstract][Full Text] [Related]
12. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance.
Lotfi K; Zackrisson AL; Peterson C
Cancer Lett; 2002 Apr; 178(2):141-9. PubMed ID: 11867198
[TBL] [Abstract][Full Text] [Related]
13. Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines.
Roovers DJ; van Vliet M; Bloem AC; Lokhorst HM
Leuk Res; 1999 Jun; 23(6):539-48. PubMed ID: 10374847
[TBL] [Abstract][Full Text] [Related]
14. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of bioreductive activation of anticancer drugs idarubicin and mitomycin C by NADH-cytochrome b5 reductase and cytochrome P450 2B4.
Celik H; Arinç E
Xenobiotica; 2013 Mar; 43(3):263-75. PubMed ID: 22928801
[TBL] [Abstract][Full Text] [Related]
16. Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Fukushima T; Yamashita T; Yoshio N; Misaki H; Yamauchi T; Imamura S; Urasaki Y; Ueda T
Leuk Res; 1999 Jan; 23(1):37-42. PubMed ID: 9933133
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells.
Tolomeo M; Gancitano RA; Musso M; Porretto F; Perricone R; Abbadessa V; Cajozzo A
Cancer Chemother Pharmacol; 1996; 39(1-2):157-61. PubMed ID: 8995514
[TBL] [Abstract][Full Text] [Related]
18. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
19. Jadomycins Inhibit Type II Topoisomerases and Promote DNA Damage and Apoptosis in Multidrug-Resistant Triple-Negative Breast Cancer Cells.
Hall SR; Toulany J; Bennett LG; Martinez-Farina CF; Robertson AW; Jakeman DL; Goralski KB
J Pharmacol Exp Ther; 2017 Nov; 363(2):196-210. PubMed ID: 28904004
[TBL] [Abstract][Full Text] [Related]
20. Redox mechanism of anticancer drug idarubicin and in-situ evaluation of interaction with DNA using an electrochemical biosensor.
Eda Satana Kara H
Bioelectrochemistry; 2014 Oct; 99():17-23. PubMed ID: 24967755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
